Dimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and...
18 October 2016 - 11:00PM
Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical
company advancing novel, adeno-associated virus (AAV) gene
therapies targeting the liver, a key organ for human metabolism,
today announced three poster presentations that highlight the
mammalian vector manufacturing platform for Dimension’s novel
clinical and preclinical product development programs. The
presentations are taking place this week during the ESGCT Congress,
which is being held in Florence, Italy, October 18-21, 2016.
In one poster, titled “Establishing a clone selection strategy
to accelerate recombinant adeno-associated virus (rAAV) producer
cell line development” (Poster #P368), Dimension researchers are
reporting on a technique that reduces the time by 50% or more to
create cell lines producing AAV vectors for use in in vivo
preclinical studies and clinical trials. A second poster –
“Particle Titer Determination and Characterization of rAAV
Molecules Using Nanoparticle Tracking Analysis and Other
Techniques” (Poster #P394) – disclosed a novel detection method
that can measure therapeutic concentrations of an AAV therapeutic
product in minutes, rather than in hours or days as required by
traditional techniques. Additionally, Dimension research featured
in a poster, titled “Molecular assay toolbox to identify
characteristics of recombinant adeno-associated virus
(rAAV)-producing cell lines” (Poster #P379), examined an array of
techniques to determine molecular characteristics correlating with
enhanced cell line productivity.
“The presentations at this year’s ESGCT conference underscore
Dimension’s leadership in innovating next-generation manufacturing
technologies for gene therapy products,” said Dr. Annalisa Jenkins,
MBBS, FRCP, Chief Executive Officer of Dimension. “We are committed
to developing a new standard in the manufacturing of AAV vectors,
one that supports the large scale and high quality we believe is
required to unlock the full potential of this field.”
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in
discovering and developing new therapeutic products for people
living with devastating rare diseases associated with the liver,
based on the most advanced, mammalian adeno-associated virus (AAV)
gene delivery technology. Dimension is actively progressing its
broad pipeline, which features programs addressing unmet needs for
patients suffering from inherited metabolic diseases, including OTC
deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a
collaboration with Bayer in hemophilia A, and a wholly owned
clinical program in hemophilia B. The company targets diseases with
readily identifiable patient populations, highly predictive
preclinical models, and well-described, and often clinically
validated, biomarkers. Founded in 2013, Dimension maintains
headquarters in Cambridge, Massachusetts.
For more information, please visit
http://www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
development of new manufacturing processes, increased production
and scale capacity. All such forward-looking statements are based
on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include the risks that the benefits of new
manufacturing processes will not be realized; Dimension's product
candidates, including its lead candidate, DTX101, will not
successfully be developed or commercialized; and the risks
described under the caption "Risk Factors" in Dimension
Therapeutics’ Quarterly Report on Form 10-Q for the quarter ended
June 30, 2016, which is on file with the Securities and Exchange
Commission, as well as other risks detailed in Dimension
Therapeutics’ additional filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Dimension Therapeutics undertakes no duty to
update this information unless required by law.
CONTACT:
Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com
Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Apr 2024 to May 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From May 2023 to May 2024